Danish Medicines Agency: Annual Medical Cannabis Safety Report Identifies No New Risks
Denmark's annual medical cannabis report for 2025 found no new safety signals despite a significant increase in prescriptions. Only three suspected adverse reactions were reported.
The Danish Medicines Agency has released its annual report detailing the use of medical cannabis products in Denmark during 2025. The report indicates that no new or changed safety risks were identified within the observed period.
According to the agency's findings, only three suspected adverse reaction cases were reported for medical cannabis use in 2025. Concurrently, the report highlights a substantial rise in the demand for these treatments, with 22,410 prescriptions dispensed to 2,465 patients. This marks a significant increase in the utilization of medical cannabis in the country.
STENOCARE A/S, listed on NASDAQ First North Growth Market, noted the publication of this report. As a participant in the Danish medical cannabis sector, the company observes the regulatory landscape and safety data. The report's findings align with the established safety profile of regulated medical cannabis products.
The Danish Medicines Agency's report serves as a key resource for monitoring the safety and efficacy of medical cannabis. The agency continues its surveillance to ensure patient well-being and provide updated information on the growing use of these therapies.